Biosafety Level 3 Core
Biosafety Level 3 Core
批准号:
9111797
负责人:
DANIEL Garrett KAVANAGH
金额:
$10.25万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
Acquired Immunodeficiency SyndromeAddressAfricaAnimalsAreaAsiaBiologyBostonCaribbean regionCell SeparationCertificationCollaborationsCommunicable DiseasesCommunitiesConsultationsContainmentDevelopmentDiseaseEnvironmentEpidemicEquipmentFacultyFlow CytometryFortuneFosteringFoundationsFutureHIVHIV InfectionsHIV/TBHome environmentHumanImageImmunologyInfectionInstitutesInstructionInternationalIntervention TrialJournalsLaboratoriesLeadLeadershipLifeMicrobiologyMicroscopyMolecularMorbidity - disease rateMusPathogenesisPlayPopulationPreventionProceduresPublicationsResearchResearch InfrastructureResearch PersonnelResourcesRiskRoleSafetyScientistSouth AfricaSouth AmericaStrategic PlanningTalentsTimeTrainingTraining and EducationUniversitiesVoiceVotingWorkanimal facilitybiocontainment facilitybiosafety level 3 facilitycellular imagingco-infectiondesignexperienceflexibilityglobal healthhumanized mouseinnovationinsightinstrumentinstrumentationlive cell imaginglive cell microscopymeetingsmembermortalitymouse modelprogramsresearch facilityresearch studysquare footsymposiumtissue cultureworking group
中文摘要
结核病和艾滋病毒感染的交叉正在增加这两种疾病的全球负担。HIV感染
极大地增加了结核病从潜伏感染转化为活动性感染的风险,结核病感染增加
艾滋病毒+人群的发病率和死亡率。2006年,中国艾滋病预防控制中心主办了全国结核病防治工作会议
混合感染,这导致成立了一个由HU CFAR成员组成的工作组,专注于TB-HLV
研究和确定一个主要的未得到满足的需求:BSL-3生物遏制设施,允许细胞
分类和成像。当大篷车研究所的新设施正在建设时,胡CFAR
会员成功地向菲利普·T和苏珊·M·拉贡基金会请愿,加入了一项最先进的
BSL-3实验室就是为了满足这些需求。这些最近落成的设施包括2240平方英尺的BSL-
3层空间、流式细胞仪和细胞分选、动物处理、成像和额外空间
容纳临时设备。在HU CFAR的支持下,这个设施现在是新创建的HU的所在地
CFAR BSL-3核心。Daniel Kavanagh博士担任PI,与Sarah Fortune博士密切合作,
国际公认的结核病研究专家,担任新成立的结核病研究小组主任
计划,并与HU CFAR结核病-艾滋病毒科学工作组密切互动。《财富》博士和
Kavanagh共同监督了一个由研究员、科学家和一名设施经理组成的团队,他们为
安全、高效的BSL-3级研究经验。这支球队的综合天赋,以及
最先进的BSL-3设施,可供HU CFAR社区使用。向HU CFAR用户提供
在设施内进行实验的培训和认证;或者,核心员工可用于
代表那些不希望进行组织培养和微生物学程序的研究人员进行标准的组织培养和微生物程序
在工厂里工作。建议的HU CFAR生物安全3级核心遵循以下具体原则
目标:
1.为正在筹划的HU CFAR社区成员提供培训和咨询
结核病相关项目
2.提供BSL-3微生物学、组织培养、活细胞显微镜、活FACS、动物
设施和特殊项目。
英文摘要
The intersection of TB and HIV infection is increasing the global burden of both diseases. HIV infection
greatly increases the risk of TB converting from latent to active infection, and TB infection increases
morbidity and mortality in the HIV+ population. In 2006, the HU CFAR sponsored a national meeting on TBHIV
coinfection, which led to the creation of a working group of HU CFAR members focused onTB-HlV
research, and identification of a major unmet need: a BSL-3 biocontainment facility that would allow for cell
sorting and imaging. When new facilities for the Ragon Institute were being constructed, the HU CFAR
Membership successfully petitioned the Phillip T and Susan M Ragon Foundation to include a state of the art
BSL-3 laboratory to meet these needs. These recently completed facilities include 2240 square feet of BSL-
3 level space, flow cytometry and cell sorting, animal handling, imaging and additional space to
accommodate temporary equipment. With HU CFAR support this facility is now home of a newly created HU
CFAR BSL-3 Core. Dr. Daniel Kavanagh serves as the PI, working closely with Dr Sarah Fortune, an
internationally recognized expert in studies of TB who serves as Director of the newly-created Ragon TB
Program, with close interactions with the HU CFAR TB-HIV Scientific Working Group. Drs. Fortune and
Kavanagh jointly supervise a team of fellows, staff scientists, and a facility manager who bring extensive
experience in safe and productive of BSL-3-level research. The combined talents of this team, as well as
state-of-the-art BSL-3 facilities, are, available to the HU CFAR community. HU CFAR users are offered
training and certification to conduct experiments within the facility; alternatively Core staff are available to
carry out standard tissue culture and microbiology procedures on behalf of researchers who do not wish to
work inside the facility. The proposed HU CFAR Biosafety Level 3 Core is guided by the following specific
aims:
1. Provide training and consultation for members of HU CFAR community members who are planning
TB related projects
2. Provide access to BSL-3 microbiology, tissue culture, live cell microscopy, live FACS, animal
facilities, and special projects.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HLA restriction and TCR affinity in HIV
-
批准号:8298440
-
项目类别:
-
资助金额:$43.88万
-
财政年份:2011
-
负责人:DANIEL Garrett KAVANAGH
-
依托单位:
Development of needle-free, vectorless, RNA-based vaccines for HIV
-
批准号:7896609
-
项目类别:
-
资助金额:$25.45万
-
财政年份:2009
-
负责人:DANIEL Garrett KAVANAGH
-
依托单位:
Development of needle-free, vectorless, RNA-based vaccines for HIV
-
批准号:7755138
-
项目类别:
-
资助金额:$21.56万
-
财政年份:2009
-
负责人:DANIEL Garrett KAVANAGH
-
依托单位:
The T cell response to rapidly evolving HIV antigens
-
批准号:7062425
-
项目类别:
-
资助金额:$5.2万
-
财政年份:2004
-
负责人:DANIEL Garrett KAVANAGH
-
依托单位:
The T cell response to rapidly evolving HIV antigens
-
批准号:6740059
-
项目类别:
-
资助金额:$4.73万
-
财政年份:2004
-
负责人:DANIEL Garrett KAVANAGH
-
依托单位:
The T cell response to rapidly evolving HIV antigens
-
批准号:6913659
-
项目类别:
-
资助金额:$4.99万
-
财政年份:2004
-
负责人:DANIEL Garrett KAVANAGH
-
依托单位:
Biosafety Level 3 Core
-
批准号:8697515
-
项目类别:
-
资助金额:$10.43万
-
财政年份:--
-
负责人:DANIEL Garrett KAVANAGH
-
依托单位:
Biosafety Level 3 Core
-
批准号:8883332
-
项目类别:
-
资助金额:$10.47万
-
财政年份:--
-
负责人:DANIEL Garrett KAVANAGH
-
依托单位:
Biosafety Level 3 Core
-
批准号:9317422
-
项目类别:
-
资助金额:$8.81万
-
财政年份:--
-
负责人:DANIEL Garrett KAVANAGH
-
依托单位:
海外基金